AstraZeneca

AstraZeneca's recent trial failure has raised concerns about the vulnerability of its pipeline premium. The company has been valued highly among European pharma firms based on consistent results.

Virginia rose to third place in CNBC’s annual ‘Top States for Business’ rankings, attributed to improvements in cost of living, housing, healthcare, and infrastructure. Governor Abigail Spanberger highlighted new laws and investments, including a $50 million boost to the Virginia Business Ready Sites Program and initiatives like InternshipsVA.

AstraZeneca's stock fell sharply after its late-stage heart drug trial for Wainua failed to reduce cardiovascular deaths and recurring heart events, causing a $27 billion drop in market value.

AstraZeneca and Ionis Pharmaceuticals reported that their heart disease drug, Wainua, failed in a pivotal trial for ATTR-CM, showing no improvement over placebo in reducing cardiovascular death and clinical events. The failure caused AstraZeneca's U.S. shares to drop 8% and London-listed shares to fall 9%, while Ionis shares fell 12%.

AstraZeneca's stock fell 9% following a heart drug trial that failed to meet its target. The decline reflects investor disappointment over the unmet clinical trial objective.

The FDA approved Trutakna, a kidney disease drug from Vera Therapeutics, for treating IgA nephropathy at an annual price of $425,000. U.K. officials are finalizing a pricing deal with AstraZeneca and Daiichi Sankyo to provide access to Enhertu, a breast cancer drug previously deemed too costly for the U.K. market.

AstraZeneca agreed to pay $34 million to settle claims that the company paid kickbacks through a free network of nurses and insurance support services to boost prescriptions in Texas Medicaid. The state alleged these actions led to unauthorized reimbursements under the Texas Health Care Program Fraud Prevention Act.

Kenneth Chien, a co-founder of Moderna, received an Hermes belt from CEO Stéphane Bancel after securing a partnership with AstraZeneca. This deal accelerated Moderna's growth, leading to significant funding and the development of mRNA-based Covid vaccines, though the planned drugs for cancer and cardiovascular disease did not materialize.

Pharmaceutical companies are developing drugs to preserve muscle mass during weight loss, addressing an issue with existing GLP-1 drugs like Ozempic. Candidates such as bimagrumab, SPX-001, and CagriSema aim to reduce fat while retaining lean mass, with Cambrian Biotech testing a drug that mimics exercise to boost metabolism.

An EU court adviser recommended rejecting the European Commission's appeals to keep vaccine contract details secret, supporting transparency campaigners' push for public access to negotiations and conflict-of-interest information. The decision upholds a lower court ruling that found the Commission failed to justify withholding key documents.

AstraZeneca's investigational GLP-1 pill, elecoglipron, demonstrated significant weight loss in a Phase 2 obesity trial (11.2% after 36 weeks) and improved blood sugar control in a diabetes trial (1.74 percentage-point A1C reduction). Results were compared to oral Ozempic, which showed a smaller A1C decrease in the same study.

AstraZeneca chief Pascal Soriot warns that the company may withhold new drugs in Europe unless countries increase spending on innovative medicines following a US trade deal.

AstraZeneca CEO Pascal Soriot stated that AI is accelerating drug development and improving decision-making in research. He highlighted AI's role in increasing the likelihood of success for medicine development.

Dr. Aradhana Sarin, CFO of AstraZeneca, outlines the company's revenue growth goals.

AstraZeneca CEO Pascal Soriot delivered remarks as the company celebrated its transfer to the NYSE. The event marks a significant milestone for the firm's stock market presence.

President Trump's most-favored-nation drug pricing deals with 17 drugmakers will be tested by three new prescription drugs set to launch soon. The drugs, Baxfendy (hypertension), Awiqli (insulin), and Veppanu (cancer), will offer the first public insight into the practical impacts of these secretive pricing agreements.

The FDA delayed a decision on AstraZeneca's breast cancer drug camizestrant due to advisory concerns over its trial design. Blackstone Life Sciences is investing $1.3 billion in Apogee Therapeutics for Phase 3 development of zumilokibart, a long-acting atopic dermatitis treatment. Kailera's experimental obesity drug, targeting three hormones, showed significant weight loss in a Phase 1 study.

The FDA has extended the decision deadline for AstraZeneca's experimental breast cancer pill, camizestrant, to review additional data after an advisory panel raised concerns about a late-stage trial's design. Brazil approved the first generic version of Novo Nordisk's Ozempic (now Ozivy) by EMS, a pharmaceutical company, which plans to sell it at 30% lower cost.

EU and US regulatory advisers have diverged in their assessment of AstraZeneca's breast cancer drug, signaling potential approval challenges. The disagreement highlights different regulatory approaches between the two regions on this oncology treatment.

The US Supreme Court declined to hear lawsuits from brand-name pharmaceutical companies against the Medicare drug price negotiation program, and the TrumpRx prescription drug discount platform is expanding with over 600 generic drugs. The expansion is a result of partnerships with Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx. This development may make remaining legal challenges more difficult for the drug industry.

AstraZeneca has received FDA approval for a hypertension drug, and the biotech industry is debating the role of China in global drug development. The FDA has also undergone leadership changes with new acting directors. AstraZeneca's approval is a significant development in the treatment of hypertension.

The Supreme Court rejected a challenge to the Medicare drug price negotiation program, declining to take up lawsuits from several pharmaceutical companies. The decision is a blow to the brand drug industry's legal campaign against the program. The court did not provide a reason for its decision.

AstraZeneca's CFO predicts 2026 will be a catalyst-rich year, signaling major events for the company.

AstraZeneca has reversed its decision to pause large-scale UK projects, pledging a £300m investment in the country after previously citing dissatisfaction with the NHS and drug pricing. The announcement, made by Keir Starmer, marks a surprise shift in the company's stance on the UK business environment.

FTSE 100 Futures and the British pound declined following earnings reports from Lloyds Banking Group and AstraZeneca. The market reaction suggests investor concerns over the companies' performance impacting broader economic indicators.

AstraZeneca's CEO warns that Japan risks falling behind without drug pricing reform. The warning highlights potential consequences for Japan's pharmaceutical market and competitiveness.